These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 7126269)
1. Mechanism of resistance to the oncolytic C-nucleoside 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC-286193). Jayaram HN; Cooney DA; Glazer RI; Dion RL; Johns DG Biochem Pharmacol; 1982 Aug; 31(15):2557-60. PubMed ID: 7126269 [No Abstract] [Full Text] [Related]
2. Studies on the mechanism of action of 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC 286193)--II. Relationship between dose level and biochemical effects in P388 leukemia in vivo. Jayaram HN; Smith AL; Glazer RI; Johns DG; Cooney DA Biochem Pharmacol; 1982 Dec; 31(23):3839-45. PubMed ID: 6130768 [TBL] [Abstract][Full Text] [Related]
3. Initial studies on the mechanism of action of a new oncolytic thiazole nucleoside, 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC 286193). Jayaram HN; Dion RL; Glazer RI; Johns DG; Robins RK; Srivastava PC; Cooney DA Biochem Pharmacol; 1982 Jul; 31(14):2371-80. PubMed ID: 6127085 [No Abstract] [Full Text] [Related]
4. The conversion of 2-beta-D-ribofuranosylthiazole-4-carboxamide to an analogue of NAD with potent IMP dehydrogenase-inhibitory properties. Cooney DA; Jayaram HN; Gebeyehu G; Betts CR; Kelley JA; Marquez VE; Johns DG Biochem Pharmacol; 1982 Jun; 31(11):2133-6. PubMed ID: 6126195 [No Abstract] [Full Text] [Related]
5. 2-beta-D-Ribofuranosylthiazole-4-carboxamide, a novel potential antitumor agent for lung tumors and metastases. Robins RK; Srivastava PC; Narayanan VL; Plowman J; Paull KD J Med Chem; 1982 Feb; 25(2):107-8. PubMed ID: 7057413 [No Abstract] [Full Text] [Related]
6. Comparative in vitro studies of Tiazofurin and a selenazole analog. Streeter DG; Robins RK Biochem Biophys Res Commun; 1983 Sep; 115(2):544-50. PubMed ID: 6138036 [TBL] [Abstract][Full Text] [Related]
7. Conversion of 2-beta-D-ribofuranosylselenazole-4-carboxamide to an analogue of NAD with potent IMP dehydrogenase-inhibitory properties. Jayaram HN; Ahluwalia GS; Dion RL; Gebeyehu G; Marquez VE; Kelley JA; Robins RK; Cooney DA; Johns DG Biochem Pharmacol; 1983 Sep; 32(17):2633-6. PubMed ID: 6137224 [No Abstract] [Full Text] [Related]
8. Effect of 2-beta-D-ribofuranosylthiazole-4-carboxamide on uptake of nucleosides by cultured L1210 cells. Karle JM; Monks A; Wolfe RM; Cysyk RL Cancer Lett; 1984 Aug; 24(1):11-8. PubMed ID: 6498794 [TBL] [Abstract][Full Text] [Related]
9. Studies on the mechanism of action of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide). VI. Biochemical and pharmacological studies on the degradation of thiazole-4-carboxamide adenine dinucleotide (TAD). Ahluwalia GS; Cooney DA; Marquez VE; Jayaram HN; Johns DG Biochem Pharmacol; 1986 Nov; 35(21):3783-90. PubMed ID: 2877671 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic synergism of tiazofurin and selected antitumor drugs against sensitive and resistant P388 leukemia in mice. Harrison SD; O'Dwyer PJ; Trader MW Cancer Res; 1986 Jul; 46(7):3396-400. PubMed ID: 3708573 [TBL] [Abstract][Full Text] [Related]
12. Selective sensitivity to tiazofurin of human leukemic cells. Jayaram HN; Pillwein K; Nichols CR; Hoffman R; Weber G Biochem Pharmacol; 1986 Jun; 35(12):2029-32. PubMed ID: 3718544 [TBL] [Abstract][Full Text] [Related]
13. Studies on the mechanism of action of tiazofurin metabolism to an analog of NAD with potent IMP dehydrogenase-inhibitory activity. Cooney DA; Jayaram HN; Glazer RI; Kelley JA; Marquez VE; Gebeyehu G; Van Cott AC; Zwelling LA; Johns DG Adv Enzyme Regul; 1983; 21():271-303. PubMed ID: 6152729 [TBL] [Abstract][Full Text] [Related]
14. Studies on the mechanism of action of 2-beta-D-ribofuranosylthiazole-4-carboxamide--V. Factors governing the response of murine tumors to tiazofurin. Ahluwalia GS; Jayaram HN; Plowman JP; Cooney DA; Johns DG Biochem Pharmacol; 1984 Apr; 33(8):1195-203. PubMed ID: 6143562 [TBL] [Abstract][Full Text] [Related]
15. Mechanism of resistance of a variant of P388 leukemia to L-(alpha S,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin). Jayaram HN; Ardalan B; Deas M; Johnson RK Cancer Res; 1985 Jan; 45(1):207-12. PubMed ID: 2578092 [TBL] [Abstract][Full Text] [Related]
16. Comparative study of in vivo development of resistance to various classes of antitumor agents in P388 leukemia. Inaba M; Fujikura R; Sakurai Y Gan; 1979 Oct; 70(5):607-13. PubMed ID: 520752 [No Abstract] [Full Text] [Related]
17. Development and cross-resistance characteristics of a subline of P388 leukemia resistant to 4'-(9-acridinylamino)-methanesulfon-m-anisidide. Johnson RK; Howard WS Eur J Cancer Clin Oncol; 1982 May; 18(5):479-87. PubMed ID: 6956514 [No Abstract] [Full Text] [Related]
18. [Role of intracellular pH in the development of resistance of leukemic cells to antineoplastic drugs]. Shestova OL; Ogloblina TA; Litinskaia LL Eksp Onkol; 1990; 12(3):61-2. PubMed ID: 2344828 [TBL] [Abstract][Full Text] [Related]
19. Use of tiazofurin to enhance the metabolism and cytotoxic activities of analogues of guanine, guanosine, and deoxyguanosine. Saunders PP; Tan MT; Spindler CD; Robins RK Cancer Res; 1987 Feb; 47(4):1022-6. PubMed ID: 3802087 [TBL] [Abstract][Full Text] [Related]
20. Tiazofurin and selenazofurin induce depression of cGMP and phosphatidylinositol pathway in L1210 leukemia cells. Parandoosh Z; Robins RK; Belei M; Rubalcava B Biochem Biophys Res Commun; 1989 Oct; 164(2):869-74. PubMed ID: 2554903 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]